Brainstorm Cell Therapeutics Inc.

BCLIOTCHealthcare● Active

$0.80

+$0.05(+6.87%)

Market Cap$8827820

P/E Ratio—

52W High$1.33

52W Low$0.46

Avg Volume15K

Open$0.74

Beta0.28

Overview

Brainstorm Cell Therapeutics Inc. (BCLI) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

BCLI · cash on hand · updated Dec 31, 2025

Core cash position

as of Dec 31, 2025

Cash & Short-Term Investments (CCE + ST Investments)

$29,000▼ -84.5% vs prior year

FY · as of Dec 31, 2025 · Reported in USD

Cash & Cash Equiv. (CCE)

$29,000

cashAndCashEquivalents

Short-Term Investments

shortTermInvestments

YoY Change vs Prior Year

-84.5%

vs prior fiscal year

Latest Quarter

$15,000

Q1 2026

Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in USD

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2025

Net cash vs debt

Cash vs Debt · Balance Sheet Health

Cash & ST Investments$29,000Cash on Hand

Total Debt$208,000Total Debt

Net Cash / Net Debt−$179,000Net Debt Position

Cash vs Debt Ratio

Cash 12%Brainstorm Cell Therapeutics Inc. cash as % of market cap: 0.33%% · MCap $0BDebt 88%

Brainstorm Cell Therapeutics Inc. carries a net debt position of $179,000. Total debt ($208,000) exceeds cash on hand ($29,000). Brainstorm Cell Therapeutics Inc. cash vs debt ratio: 12% cash / 88% debt.

Net Cash = Cash & ST Investments − Total Debt$29,000 − $208,000 = −$179,000

Cash on hand history

annual cash on hand trend · Cash & Short-Term Investments

YoY Increase

YoY Decrease

Latest Year

BCLI annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

BCLI cash & short-term investments history

DatePeriodCash & ST InvestmentsYoY Change

Dec 31, 2025LatestFY$0.0M-84.5%

Dec 31, 2024FY$0.2M-85.6%

Dec 31, 2023FY$1.3M-56.4%

Dec 31, 2022FY$3.0M-86.5%

Dec 31, 2021FY$22.1M-47.3%

BCLI cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

BCLI vs peers · cash on hand

#CompanyCash & ST Inv.Market CapCash/MCapRelative

UnitedHealth Group Incorporated

Eli Lilly and Company

Brainstorm Cell Therapeutics Inc.YOU

BCLI

$0.0M$9M0.3%

Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Brainstorm Cell Therapeutics Inc. (BCLI) cash on hand as of December 31, 2025 is $29,000, comprising $29,000 in cash and cash equivalents (CCE) plus $0 in short-term investments — reported as Brainstorm Cell Therapeutics Inc. cash and short-term investments on the balance sheet (10-K filing). Also referred to as Brainstorm Cell Therapeutics Inc. cash reserves or cash position.

Brainstorm Cell Therapeutics Inc. annual cash on hand history shows decreased -84.5% in 2025: decreased -84.5% in 2025. Brainstorm Cell Therapeutics Inc. cash reserves in 2025 reflect the company's capital allocation strategy.

Brainstorm Cell Therapeutics Inc. carries total debt of $208,000 against cash of $29,000, resulting in a net debt position of -$179,000. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.

Financial statements Free cash flow Net income Revenue Market cap P/E ratio Earnings Price history

Frequently asked questions

BCLI cash on hand · 5 questions

As of December 31, 2025, Brainstorm Cell Therapeutics Inc. (BCLI) has $29,000 in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $29,000 in cash and cash equivalents (CCE) plus $0 in short-term investments. Latest quarter (March 31, 2026): $15,000. Data sourced from the annual 10-K filing via FMP.

BCLI cash on handBCLI cash reservesBCLI cash 2025how much cash does BCLI have

▸ Source: FMP /balance-sheet-statement · US GAAP · Brainstorm Cell Therapeutics Inc. · Brainstorm Cell Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2025